Acute Myelomonocytic Leukemia
Image and content excerpted from the VisualDx clinical decision support system.
VisualDx images show variation in age, skin color, and disease stage. VisualDx has 7 images of Acute Myelomonocytic Leukemia.
Full text and additional images for Acute Myelomonocytic Leukemia are available in the following VisualDx packages:
205.00 – Myeloid leukemia acute without mention of having achieved remission
C92.50 – Acute myelomonocytic leukemia, not having achieved remission
SynopsisAcute myelomonocytic leukemia (AMML) is a subtype of acute myeloid leukemia (AML) marked by differentiation toward both granulocytic and monocytic cell lines. AML is more common than acute lymphocytic leukemia (ALL) in neonates and infants, and AMML is the second most common subtype of AML seen in this population, accounting for approximately 17% of reported cases. Most cases of congenital and infant leukemia are thought to be secondary to chromosomal aberrations acquired in utero.
The presenting sign is of leukemia cutis in about half of patients, with leukemia cutis preceding other signs of leukemia by as long as 4 months. Patients with AML also show a high leukocyte count, hepatosplenomegaly, and a high likelihood for CNS involvement. With leukemias that present later in infancy, signs and symptoms are often less specific and include low-grade fever, pallor, lethargy, hepatosplenomegaly, bleeding diathesis, diarrhea, or failure to thrive. CNS involvement and male sex are independent adverse prognostic factors. The prognosis of neonatal/infant AML is generally bleak with or without chemotherapy; the overall survival is only 25% at 3 years.